Cell and cytokine analyses from bronchoalveolar lavage in non-critical COVID-19 pneumonia

Rolland‐Debord, Camille; Piéroni, Laurence; Bejar, Farah; Milon, Audrey; Choinier, Pascaline; Blin, Emmanuelle; Bravais, J.; Halitim, P; Letellier, A.; Camuset, Juliette; Parrot, Antoine; Fajac, Anne; Cadranel, Jacquès

doi:10.1007/s11739-023-03341-5

Cited by 2 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common symptoms associated with COVID-19 infection include fever, dry cough, fatigue, shortness of breath, loss of smell or taste, and headaches [20]. As symptoms progress in severity, some patients may develop severe pneumonitis, "cytokine storm" (i.e., hyperinflammation), intravascular coagulation, and thrombotic complications [21][22][23][24]. In cases where the disease severity reaches a critical stage and patients are not able to recover through medical intervention, further complications such as acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS)/septic shock, and multi-organ failure can arise that are ultimately fatal.…”

Section: Introductionmentioning

confidence: 99%

Engineering Materials and Devices for the Prevention, Diagnosis, and Treatment of COVID-19 and Infectious Diseases

Soto,

Linsley,

Song

et al. 2023

Nanomaterials

View full text Add to dashboard Cite

Following the global spread of COVID-19, scientists and engineers have adapted technologies and developed new tools to aid in the fight against COVID-19. This review discusses various approaches to engineering biomaterials, devices, and therapeutics, especially at micro and nano levels, for the prevention, diagnosis, and treatment of infectious diseases, such as COVID-19, serving as a resource for scientists to identify specific tools that can be applicable for infectious-disease-related research, technology development, and treatment. From the design and production of equipment critical to first responders and patients using three-dimensional (3D) printing technology to point-of-care devices for rapid diagnosis, these technologies and tools have been essential to address current global needs for the prevention and detection of diseases. Moreover, advancements in organ-on-a-chip platforms provide a valuable platform to not only study infections and disease development in humans but also allow for the screening of more effective therapeutics. In addition, vaccines, the repurposing of approved drugs, biomaterials, drug delivery, and cell therapy are promising approaches for the prevention and treatment of infectious diseases. Following a comprehensive review of all these topics, we discuss unsolved problems and future directions.

show abstract

Section: Introductionmentioning

confidence: 99%

Engineering Materials and Devices for the Prevention, Diagnosis, and Treatment of COVID-19 and Infectious Diseases

Soto,

Linsley,

Song

et al. 2023

Nanomaterials

View full text Add to dashboard Cite

show abstract

Uncovering the Contrasts and Connections in PASC: Viral Load and Cytokine Signatures in Acute COVID-19 versus Post-Acute Sequelae of SARS-CoV-2 (PASC)

Compeer,

Neijzen,

van Lelyveld

et al. 2024

Biomedicines

View full text Add to dashboard Cite

The recent global COVID-19 pandemic has had a profound and enduring impact, resulting in substantial loss of life. The scientific community has responded unprecedentedly by investigating various aspects of the crisis, particularly focusing on the acute phase of COVID-19. The roles of the viral load, cytokines, and chemokines during the acute phase and in the context of patients who experienced enduring symptoms upon infection, so called Post-Acute Sequelae of COVID-19 or PASC, have been studied extensively. Here, in this review, we offer a virologist’s perspective on PASC, highlighting the dynamics of SARS-CoV-2 viral loads, cytokines, and chemokines in different organs of patients across the full clinical spectrum of acute-phase disease. We underline that the probability of severe or critical disease progression correlates with increased viral load levels detected in the upper respiratory tract (URT), lower respiratory tract (LRT), and plasma. Acute-phase viremia is a clear, although not unambiguous, predictor of PASC development. Moreover, both the quantity and diversity of functions of cytokines and chemokines increase with acute-phase disease severity. Specific cytokines remain or become elevated in the PASC phase, although the driving factor of ongoing inflammation found in patients with PASC remains to be investigated. The key findings highlighted in this review contribute to a further understanding of PASC and their differences and overlap with acute disease.

show abstract

Cell and cytokine analyses from bronchoalveolar lavage in non-critical COVID-19 pneumonia

Cited by 2 publications

References 29 publications

Engineering Materials and Devices for the Prevention, Diagnosis, and Treatment of COVID-19 and Infectious Diseases

Engineering Materials and Devices for the Prevention, Diagnosis, and Treatment of COVID-19 and Infectious Diseases

Uncovering the Contrasts and Connections in PASC: Viral Load and Cytokine Signatures in Acute COVID-19 versus Post-Acute Sequelae of SARS-CoV-2 (PASC)

Contact Info

Product

Resources

About